Among pharmacological Nrf2 activators, dimethyl fumarate (Tecfidera), monomethyl fumarate (Bafiertam), and diroximel fumarate (Vumerity) have been approved for the treatment of multiple sclerosis. This evidence concerns the gene NFE2L2 and multiple sclerosis.